Table 1 Recent patent applications in bacteriotherapy
Patent number | Description | Assignee | Inventor | Priority application date | Publication date |
|---|---|---|---|---|---|
WO 2012159023 | Assessing the presence or risk of development of encephalopathy in a patient with liver disease by analyzing gut microflora, comparing the microbiome signature, and concluding patient has or is at risk of developing encephalopathy. | Virginia Commonwealth University (Richmond, VA, USA), US Department of Veterans Affairs (Washington, DC), George Mason University (Fairfax, VA, USA) | Bajaj J, Gillevet PM, Sanyal A | 5/19/2011 | 11/22/2012 |
WO 2012122522 | A model gnotobiotic animal comprising a cultured gut microbial community, including a composition comprising an in vitro cultured collection of a gut microbial community or clonally arrayed cultured collection of a gut microbial community, a method for determining the effect of a perturbation on a gut microbial community and a method for predicting variations in abundance of a member of a gut microbiome of a host in response to a proposed diet. | Washington University (St. Louis, MO, USA) | Faith JJ, Goodman A, Gordon JI, Kallstrom G, McNulty NP, Rey FE, Ridaura V | 3/9/2011 | 9/13/2012 |
WO 2012118535 | A biologically active composition isolated from biofilm, a medium in which biofilm is grown or a biological sample extracted from a patient and then grown as biofilm, where the biological activity is the ability to modulate a microbiome to which the composition is administered. | Quorum Innovations (Sarasota, FL, USA) | Berkes EA, Monsul NT | 3/1/2011 | 9/7/2012 |
WO 2012050513 | A method for identifying an individual at risk of developing cardiovascular disease, involving obtaining an oral sample from the individual, and determining the presence of specific bacterial groups or species in the oral sample that indicates a risk of developing cardiovascular disease. | Baeckhed F | Baeckhed F | 10/11/2010 | 4/19/2012 |
WO 2012033814 | Inhibiting disease caused by Clostridium in a subject, comprising administering at least one antibiotic to the subject and contacting the environment of the subject with a nontoxigenic strain of Clostridium, where the subject is maintained in the environment for a time sufficient to allow the colonization of the gastrointestinal tract of the subject by the nontoxigenic Clostridium. | ViroPharma (Exton, PA, USA) | Broom C, Tatarowicz WA | 9/10/2010 | 3/15/2012 |
WO 2012016287 | A delivery vehicle, formulation, composition, pharmaceutical preparation, product of manufacture, container or device for prophylactic or therapeutic use, containing an entire or substantially entire microbiota, or complete or partial fecal flora. | Borody TJ | Borody TJ | 8/4/2010 | 2/9/2012 |
WO 2011107482 | A method of diagnosing and treating obesity, involving determining whether at least one gene provided in the patent specification is absent from an individual's gut microbiome. | Institut National de la Recherche Agronomique (Paris), Ehrlich S | Ehrlich S | 3/1/2010 | 9/9/2011 |
WO 2011107481 | A method of diagnosing inflammatory bowel disease, comprising determining whether at least one gene provided in the patent specification is absent from an individual's gut microbiome. | Institut National de la Recherche Agronomique (Paris) | Ehrlich S | 3/1/2010 | 9/9/2011 |
WO 2011094027 | Bacteriotherapy for Clostridium difficile colitis, comprising receiving a set of donor fecal samples, receiving a characteristic of each of the set of donor fecal samples, storing a portion of each fecal sample and indexing. | Hlavka EJ, MikrobEX (Minneapolis, MN, USA) | Hlavka EJ | 2/1/2010 | 8/4/2011 |
